In This Section

Continuing Medical Education

Accreditation StatemenT

Credit Designation Statement

AACR has designated this live activity for a maximum of 16.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.

Claiming (CME) Credit

Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by July 2, 2024. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.

Request For Credit Survey

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 16.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.  

To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.

Printable List of CME-Designated Sessions

Statement of Educational Need, Target Audience, and Learning Objectives

Bladder cancer (BC) is the most common malignancy of the urogenital tract. More than 1.6 million people are living with BC worldwide. Over 80,000 new cases and 17,000 deaths are expected in the United States alone in 2022. Bladder cancer incidence is also drastically higher in males than females across geographical, racial, and socioeconomic strata. Despite potential differences in tumor biology, however, male, and female bladder cancer patients are still clinically managed in highly similar ways.

While there were few advances in clinical management of bladder cancer over the past three decades, this trend has been considerably altered over the past several years. Advances in our understanding of bladder cancer biology, coupled with large-scale gene expression and sequencing efforts, have led to more clinically favorable targeted treatments and effective immunotherapies. These advances have also provided clinicians with the ability to characterize bladder cancer into distinct molecular and histological subtypes. Laboratory discoveries have also led to increasing integration of next-generation “omics” technologies into clinical management.

The challenges lying ahead include the development of companion biomarkers to assign patients to the therapies they are most responsive to, and more effective combination therapy with checkpoint blockade immunotherapies, small molecules, and other biologically based therapies.

This multidisciplinary program will span from basic research to clinical care.  The plenary sessions on management of non-invasive disease, neoadjuvant and bladder-sparing approaches to invasive disease, and management of metastatic disease are likely to be of particular interest to physicians and other healthcare professionals involved in diagnosing and treating bladder cancer, urology, radiation oncology and pathology residents and medical oncology fellows.

After participating in this CME activity, physicians should be able to:

  • Assess the molecular tools used in the discovery and validation of biomarkers, driver genes and hormones in bladder cancer
  • Identify new areas for collaborative study among bladder cancer surgeons clinicians, radiation oncologists, and basic researchers.
  • Describe the mechanisms of action underlying therapies used to treat patients with bladder cancer in various stages of disease (non-invasive, invasive, metastatic), and understand the basics of their molecular rationale
  • Identify emerging AI tools for clinical usage


It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed all financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships for these individuals have been mitigated.

Planner and Speaker Financial Index

Acknowledgment of Financial or Other Support

The AACR gratefully acknowledges the following commercial supporters for their Professional Educational Grants:

  • Bristol Myers Squibb
  • Merck
  • Pfizer

Questions about CME?

Please read our frequently asked questions. If you still have questions, contact the Office of CME at (215) 440-9300 or [email protected].